Bellicum Pharmaceuticals Alpha and Beta Analysis
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bellicum Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bellicum Pharmaceuticals over a specified time horizon. Remember, high Bellicum Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bellicum Pharmaceuticals' market risk premium analysis include:
Beta 0.44 | Alpha 1.06 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Bellicum |
Bellicum Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bellicum Pharmaceuticals market risk premium is the additional return an investor will receive from holding Bellicum Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bellicum Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bellicum Pharmaceuticals' performance over market.| α | 1.06 | β | 0.44 |
Bellicum Pharmaceuticals Fundamentals Vs Peers
Comparing Bellicum Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bellicum Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Bellicum Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bellicum Pharmaceuticals or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Bellicum Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bellicum Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bellicum Pharmaceuticals to competition |
| Fundamentals | Bellicum Pharmaceuticals | Peer Average |
| Return On Equity | -1.06 | -0.31 |
| Return On Asset | -0.61 | -0.14 |
| Operating Margin | (19.69) % | (5.51) % |
| Current Valuation | (38.62 M) | 16.62 B |
| Shares Outstanding | 9.5 M | 571.82 M |
| Shares Owned By Insiders | 4.19 % | 10.09 % |
| Shares Owned By Institutions | 29.30 % | 39.21 % |
Bellicum Pharmaceuticals Opportunities
Bellicum Pharmaceuticals Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Bellicum Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bellicum or other pink sheets. Alpha measures the amount that position in Bellicum Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Bellicum Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Bellicum Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bellicum Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bellicum Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bellicum Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Bellicum Pharmaceuticals' management manipulating its earnings.
| 10th of August 2023 Upcoming Quarterly Report | View | |
| 9th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Bellicum Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |